title: [Clinical study on recombinant humanized anti-CD25 monoclonal antibody used for treating steroid-resistant acute graft versus host disease following allo-hematopoietic stem cell transplantation].
abstract: This study was purposed to investigate the efficacy and feasibility of recombinant humanized anti-CD25 monoclonal antibody for treating steroid-resistant acute graft-versus-host disease (aGVHD ) following allo-hematopoietic stem cell transplantation (allo-HSCT) . Twenty-one cases with II-IV grade steroid-resistant aGVHD after allo-HSCT were treated by intravenous injection of recombinant humanized anti-CD25 monoclonal antibody at a dose of 1 mg/(kg·d) on days 1, 4, 8. Injection was repeated after 1 week for the patients who did not achieve CR. The results indicated that 13 cases (61.9%) got complete response (CR), 4 cases out of them have been still in disease-free survival, 8 cases have been in survival with mild cGVHD, 1 cases died from AML relapse, 6 cases (28.57%) got partial response (PR), 3 cases out of them have been in survival with mild cGVHD, 3 case died from pulmonary infection, 2 cases without response died from GVHD. Overall response rate was 90.5% and long term survival rate was 71.48%. There were no infusion-associated side-effects after treatment with recombinant humanized anti-CD25 monoclonal antibody.It is concluded that recombinant humanized anti-CD25 monoclonal antibody is effective and feasible for treatment of steroid-refractory grade II-IV aGVHD after allo-HSCT.
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Li
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Chun-Ji
authors.initials: CJ
authors.lastname: Gao
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Wan-Ming
authors.initials: WM
authors.lastname: DA
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Yong-Bin
authors.initials: YB
authors.lastname: Cao
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Xu
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Ya-Mei
authors.initials: YM
authors.lastname: Wu
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Bei
authors.initials: B
authors.lastname: Liu
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Zhou-Yang
authors.initials: ZY
authors.lastname: Liu
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Bei
authors.initials: B
authors.lastname: Yan
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Song-Wei
authors.initials: SW
authors.lastname: Li
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
authors.forename: Xue-Liang
authors.initials: XL
authors.lastname: Yang
authors.affiliation: Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China. E-mail: xiongwuxiao@sohu.com.
authors.forename: Xiao-Xiong
authors.initials: XX
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006728:Hormones / Q000494:pharmacology; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D006728:Hormones; D053645:Interleukin-2 Receptor alpha Subunit